Compare BBCP & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBCP | OCGN |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.1M | 474.8M |
| IPO Year | 2017 | 2014 |
| Metric | BBCP | OCGN |
|---|---|---|
| Price | $9.08 | $0.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $13.50 | $12.17 |
| AVG Volume (30 Days) | 131.8K | ★ 6.6M |
| Earning Date | 09-03-2026 | 11-04-2026 |
| Dividend Yield | ★ 5.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $392,867,000.00 | N/A |
| Revenue This Year | $9.73 | $12.33 |
| Revenue Next Year | $5.12 | $10.95 |
| P/E Ratio | $130.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.56 | $0.79 |
| 52 Week High | $12.19 | $2.73 |
| Indicator | BBCP | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.34 | 28.10 |
| Support Level | $8.89 | N/A |
| Resistance Level | $9.64 | $1.12 |
| Average True Range (ATR) | 0.31 | 0.06 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 29.03 | 11.94 |
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators enables it to deliver concrete placement solutions. The company's operating segments include U.S. Concrete Pumping, U.K. Operations, and U.S. Concrete Waste Management Services, with the majority of revenue generated from the U.S. Concrete Pumping segment. Geographically, it operates in the United States and the United Kingdom, generating majority of its revenue from the United States.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").